Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13910-48-0,N1-Benzylpropane-1,3-diamine,as a common compound, the synthetic route is as follows.

c) methyl [(4Z)-4-(4-benzyl-l,4-diazepan-2-ylidene)-l-(2-chlorophenyl)-5-oxo-4,5- dihydro-lH-pyrazol-3-yl] acetate Compound of Formula (II), Scheme 1)To a solution of the above obtained methyl [4-(chloroacetyl)-l-(2-chlorophenyl)-5- hydroxy-lH-pyrazol-3-yl]acetate (Compound of Formula (V), 1.88 mmol, 1 eq.) in 3 mL of acetonitrile was added, slowly at zero degree Celsius, N-benzylpropane-l ,3-diamine (0.277 mg, 0.9 eq.). The reaction mixture was stirred at 0C for 0.5 h. The resulting solution was purified by silica plug using ethylacetate/0.1% triethylamine. The solvent was evaporated in vacuo and allowed to isolate a red solid which proved to be the pure methyl [(4Z)-4-(4- benzyl-l,4-diazepan-2-ylidene)-l-(2-chlorophenyl)-5-oxo-4,5-dihydro-lH-pyrazol-3-yl] acetate (0.530 g). Yield 71 %. MS(ESI+): 454.0., 13910-48-0

13910-48-0 N1-Benzylpropane-1,3-diamine 83811, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; GENKYOTEX SA; PAGE, Patrick; GAGGINI, Francesca; LALEU, Benoit; WO2011/36651; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

To a stirred solution of (25,5 ?)-6- hydroxy-A^-(lH-imidazol- l-ylacetyl)-7-oxo- l,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (10.3 g, 33.4 mmol, product obtained in step 4) in dimethylformamide (70 ml) was added dimethylformamide sulfur trioxide complex (6.45 g, 42.1 mmol). The reaction mixture was stirred at 10- 15C. The progress of reaction was monitored by thin layer chromatography using mixture of chloroform and methanol (8:2) as solvent. After completion of the reaction, solution of tetrabutyl ammonium acetate (12.69 g, 42 mmol) in water (43 ml) was added to the reaction mixture under stirring. After complete conversion to tetrabutylammoinum salt, the volatiles were removed under vacuum at 40-45 C. The obtained residue was partitioned in mixture of dichloro methane and water (140 ml + 140 ml). The organic layer was dried over anhydrous sodium sulfate and distilled to get 23 g of crude product. The crude product was purified by column chromatography using 100-200 mesh silica gel using mixture of chloroform and methanol as an eluent. The pure fractions were collected and were concentrated to obtain 12 g of tetrabutyl ammonium salt of (2S,5R)-iV-(lH- imidazol- l-ylacetyl)-7-oxo-6-(sulfooxy)- l,6-diazabicyclo[3.2.1]octane-2-carbohydrazide in 54.15% yield, 10534-59-5

As the paragraph descriping shows that 10534-59-5 is playing an increasingly important role.

Reference£º
Patent; WOCKHARDT LIMITED; TADIPARTHI, Ravikumar; PATIL, Vijaykumar Jagdishwar; DEKHANE, Deepak; SHAIKH, Mohammad Usman; BIRAJDAR, Satish; DOND, Bharat; PATEL, Mahesh Vithalbhai; (100 pag.)WO2017/81615; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

109073-77-0, [2,2′-Bipyridine]-4,4′-diyldimethanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Cobalt(II) tetrafluoroborate hexahydrate (156mg, 0.46mmol) was added to 4,4?-Bis(hydroxymethyl)-2,2?-bipyridine 8 (408mg, 1.89mmol) dissolved in absolute ethanol (37mL). The solution was refluxed under stirring for 24h, concentrated and dried under vacuum. The solid was dissolved in a minimum of methanol and dichloromethane was added slowly. The formed precipitate was filtrated and washed with dichloromethane, leading to a yellow solid. Yield: 95%,, 109073-77-0

The synthetic route of 109073-77-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; He; Fontmorin; Hapiot; Soutrel; Floner; Fourcade; Amrane; Geneste; Electrochimica Acta; vol. 207; (2016); p. 313 – 320;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

54761-04-5, Ytterbium(III) trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

54761-04-5, General procedure: These were all prepared in the same way: the example given for Ir?Eu is typical. A mixture of Ir?A (0.043g, 0.04mmol) and Eu(OTf)3 (0.024g, 0.04mmol) in anhydrous MeOH under Ar was stirred for 30min. To this was slowly added a solution of NaOH (1M in MeOH) such that the apparent pH was maintained at 5. The reaction mixture was then heated to 50C with constant stirring for 48h. After cooling the reaction mixture the solvent was evaporated under reduced pressure. The residue was dissolved in minimum amount of MeOH and re-precipitated by the gradual addition of ether. This dissolution/re-precipitation process was repeated several times and the light yellow solid mass was collected by filtration to give Ir?Eu in 60-70% yield.

As the paragraph descriping shows that 54761-04-5 is playing an increasingly important role.

Reference£º
Article; Jana, Atanu; Pope, Simon J.A.; Ward, Michael D.; Polyhedron; vol. 127; (2017); p. 390 – 395;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

56-54-2,56-54-2, (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The alkaloid (12.3 mmol, 1 eq.) and the appropriate substituted benzylic halide derivative(12.3 mmol, 1 eq.) were dissolved in THF (40 mL) with addition of a trace of NaI. The mixture washeated to reflux overnight and then cooled and stirred at ambient temperature for 1 h. In most cases theproduct precipitated as an off-white solid, but where this was not the case and the mixture containedonly a small amount of solid or no solid at all, then diethyl ether (20 mL) was added dropwise.The solid was removed via filtration and washed with THF (50 mL) or ether:THF, (1:1, v/v, 50 mL)and was dried under reduced pressure at 40 C. Where the solid formed was not a fine powder it was then taken up in DCM and this solution was then added dropwise to rapidly stirring ether (100 mL).This usually gives a finely divided solid that could be filtered and dried. (Note: The cinchonine derivedPTCs are usually very insoluble. The quinidine derived PTCs are often completely soluble at the endof the reaction.) The di(t-butyl)benzyl PTC was prepared according to the standard procedure aboveand was filtered directly from the reaction mixture.

As the paragraph descriping shows that 56-54-2 is playing an increasingly important role.

Reference£º
Article; Zhang, Tao; Scalabrino, Gaia; Frankish, Neil; Sheridan, Helen; Molecules; vol. 23; 7; (2018);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2304-30-5,Tetrabutylphosphonium chloride,as a common compound, the synthetic route is as follows.

2. Preparation of 2-Chlorosulfonyl-7-fluoro-5-methoxy-[1,2,4]triazolo[1,5-c]pyrimidine A mixture of 5.0 g (13 mmol) of 2,2′-dithiobis-(7-fluoro-5-methoxy[1,2,4]triazolo[1,5-c]pyrimidine), 75 mL of dichloromethane, 25 mL of water, and 0.3 g (1.0 mmol) tetrabutylphosphonium chloride was cooled to 3 C. and 6.0 g (8.5 mmol) of chlorine gas was added with stirring and cooling. The mixture was allowed to react at 0 to 3 C. with stirring for 2 hours by which time the initial slurry had become clear leaving two liquid phases. The phases were separated and the organic phase was concentrated by evaporation under reduced pressure to obtain 7.5 g of the title compound in impure form as a white solid. 1 H NMR Spectrum (300 MHz) in CDCl3: 6.96(s, 1 H), 5.29(s, 1 H), 4.40(s, 3 H)., 2304-30-5

The synthetic route of 2304-30-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Dow AgroSciences LLC; US6162915; (2000); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1662-01-7, 4,7-Diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Tris(6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-octanedionate)mono(bathophenanthroline) praseodymium(III), [Pr(fod)3(bath)] or complex 3, was obtained by mixing of equimolar quantities tris(6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-octanedionate)praseodymium(III) (1.026g, 1mmol) and bathophenanthroline [4,7-diphenyl-1,10-phenanthroline 97%, CAS No. 1662-01-7, Sigma-Aldrich] (0.332g, 1mmol) in methanol. The mixture was heated to 75C and stirred overnight, then washed with dioxane, and finally dried in vacuum to give the product in 86% yield (based in Pr). Crystals suitable for X-ray analysis were obtained by slow evaporation of a methanol-dioxane solution at room temperature (RT).

1662-01-7, As the paragraph descriping shows that 1662-01-7 is playing an increasingly important role.

Reference£º
Article; Pereira; Costa; Feldl; Maria; Seixas de Melo; Martin-Ramos; Martin-Gil; Ramos Silva; Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy; vol. 172; (2017); p. 25 – 33;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

Example 4- Synthesis of tri-tert-butyl 2,2′,2′-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate To a solution of product 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (572.7 mg, 1 mmol) in dry DMF (15 mL), amino-maleimide 137 (483.3 mg, 1 mmol) was added with HATU (272 mg, 1.4 mmol) and DIPEA (360 muL, 1.84 mmol). The mixture was stirred overnight at room temperature. After removing the solvent under the vacuum, the crude product was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 90:10) to give compound tri-tert-butyl 2,2′,2′-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate as a white foam (396 mg, 57 %). Rf : 0.3 (CH2Cl2/MeOH, 90:10). 1H NMR (300MHz, CDCl3) delta 8.30 (b, 1H, NH), 6.86 (s,2H, H6′), 3.78-3.54 (br, 4H, H3′, H4′), 3.54 (br, 4H, H13, H1′), 3.48 (br, 4H, H8), 3.09-2.99 (m, 8H, H2, H3), 2.97-2.86 (m, 8H, H5, H6), 1.46 (s, 18H, H12), 1.45 (s, 9H, H17). 13C NMR (75MHz, CDCl3) delta 171.6 (C2′), 171.0 (C5′), 170.4 (C9, C14), 134.2 (C6′), 81.5 (C16), 81.3 (C11), 57.8 (C1′), 55.7-55.2 (C8, C13), 54.1-51.5 (C2, C3), 51.0-48.9 (C5, C6), 38.0 (C4′), 32.7 (C3′), 27.8 (C17), 27.6 (C12). MS (ESI) : m/z 695 [M + H]+.

137076-54-1, 137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Institut Curie; Centre National de la Recherche Scientifique; The designation of the inventor has not yet been filed; EP2740491; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.100125-12-0,3,8-Dibromo-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: A mixture of stoichiometric amounts of sodium tetrafluoroborate (0.110 g, 1.0 mmol) in 10 cm3 water and 3-bromo-phen (0.259 g, 1.0 mmol) in 40 cm3 ethanol was refluxed for 2 h. The mixture was cooled to room temperature and concentrated to nearly dry using a rotatory evaporator, and then the resulting precipitate 2 was filtered and washed by diethyl ether and dried in a vacuum. Yield: 0.28 g (75.9%).

100125-12-0, As the paragraph descriping shows that 100125-12-0 is playing an increasingly important role.

Reference£º
Article; Qian, Hui-Fen; Liu, Yuan; Tao, Tao; Gu, Ke-Hua; Yin, Gui; Huang, Wei; Inorganica Chimica Acta; vol. 405; (2013); p. 1 – 8;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10534-59-5, Tetrabutylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 3: Synthesis of tetrabutyl ammonium salt of (25)-pyrrolidin-2-yl-methyl {[(25, 5 f)-7- oxo-6-(sulfooxy)-l,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}carbamate: To a stirred solution of (25)-pyrrolidin-2-yl- methyl { [(25, 5R)-7-oxo-6-(hydroxy)-l,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl} carbamate (0.984 g, 0.002 mol) in dimethylformamide (10 ml) was added dimethylformamide sulfur trioxide complex (0.548 g, 0.0035 mol) in one portion under stirring at 10C. The reaction mass was stirred at the same temperature for 30 minutes and allowed to warm to room temperature. After 1 hour, a solution of tetrabutylammonium acetate (1.05 g, 0.0035 mol) in dicholoromethane (2 ml) was added to the reaction mixture under continuous stirring. After 1 hour of stirring the solvent from the reaction mixture was evaporated under reduced pressure to obtain an oily residue. The oily mass was co-evaporated with xylene (2×10 ml) to obtain thick mass. This mass was partitioned between dichloromethane (10 ml) and water (10 ml). The combined organic extracts were washed with water (3×10 ml) and dried over anhydrous sodium sulfate.The solvent was evaporated under reduced pressure and the resulting oily mass was triturated with ether (3×10 ml), each time the ether layer was decanted and finally the residue was concentrated under reduced pressure to obtain 1.2 g of the titled product as white foam in 80% yield., 10534-59-5

10534-59-5 Tetrabutylammonium acetate 82707, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; WOCKHARDT LIMITED; TADIPARTHI, Ravikumar; PATIL, Vijaykumar Jagdishwar; KALE, Amol; SHAIKH, Mohammad Usman; PATEL, Mahesh Vithalbhai; (65 pag.)WO2016/116788; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI